Hi, There! This week, the intersection of AI and pharma reached a new inflection point. Eli Lilly unveiled the most powerful AI supercomputer in pharmaceutical history, AstraZeneca doubled down on agentic oncology AI, and the U.S. government made the unprecedented decision to ban an AI company over safety principles. Meanwhile, the Grok deepfake scandal escalated into a global regulatory crisis. Whether you're building models or building policy, this is the week that defined 2026's AI landscape.
🚀 EVENT OF THE WEEK
On February 27, 2026, Eli Lilly inaugurated LillyPod in Indianapolis — the most powerful AI factory wholly owned and operated by a pharmaceutical company. Built on NVIDIA's DGX SuperPOD architecture with 1,016 Blackwell Ultra GPUs, it delivers over 9,000 petaflops of AI performance and was assembled in just four months.
Lilly's genomics team can now harness 700 terabytes of data using over 290 terabytes of high-bandwidth GPU memory. The supercomputer will train protein diffusion models, small-molecule graph neural networks, and genomics foundation models — enabling genome analysis at population scale, exploration of billions of chemical possibilities, and AI across clinical development and manufacturing.
Why this matters: LillyPod signals that Big Pharma is no longer a customer of AI — it's becoming an AI company. When a drug maker builds compute infrastructure that rivals tech giants, it fundamentally changes the power dynamics of who controls AI-driven drug discovery.
Key takeaways:
- 1,016 Blackwell Ultra GPUs delivering 9,000+ petaflops of AI performance
- Will train protein diffusion models, molecular GNNs, and genomics foundation models
- First pharma company to own and operate AI infrastructure at this scale
⚡ Quick Updates
- AstraZeneca: Finalized its acquisition of Modella AI, embedding multimodal foundation models and agentic software into its oncology R&D pipeline. The goal: reduce lab-to-clinic timelines by 20% or more, with tools deployed in Phase II and III trials for biomarker-driven patient selection. OncoDailyA
- Google DeepMind: Released AlphaGenome, a unifying DNA sequence foundation model published in Nature. It advances regulatory variant-effect prediction by unifying long-range context, base-level precision, and state-of-the-art performance across a wide spectrum of genomic tasks. Google DeepMind
- AI in Genomics Market: A March 3 report projects dramatic growth through 2040, driven by next-generation sequencing data and ML-driven drug discovery. 80% of organizations plan to increase AI budgets, with 23% expecting to double spending. GlobeNewsWire
- OpenAI & Pentagon: Hours after Anthropic's federal ban, OpenAI announced a deal to provide AI for classified Pentagon networks — sparking debate about whether safety commitments survive when billions in government contracts are at stake. NPR
- EU AI Act: High-risk provisions take effect August 2, 2026, potentially classifying some drug development AI as high-risk. Combined with the FDA's expected AI guidance finalization, this creates a pivotal regulatory year for pharmaceutical AI globally. Drug Target Review
📚 Top Research Papers
Institution: arXiv (2603.03237v1) — q-bio.QM
A groundbreaking application of topological data analysis to cancer biology. Uses persistent homology to quantify higher-order spatial interactions between different cell types in tumor microenvironments. Validated on synthetic tumor models and real colorectal cancer tissue, the framework identifies spatial patterns that change significantly during disease progression.
Computational Pathology
Institution: arXiv (2603.03258v1) — cs.AI
This safety study examines how language model agents drift from objectives in clinical environments. While models resist direct adversarial pressure, they inherit drift when conditioned on weaker agents' trajectories. Tested in ER triage and stock-trading settings, only GPT-5.1 maintained consistent resilience — critical findings for healthcare AI deployment.
AI Safety in Healthcare
Institution: AstraZeneca / medRxiv
AstraZeneca's Predictive Biomarker Modeling Framework uses contrastive learning to automatically discover predictive biomarkers for immuno-oncology trials. PBMF improved patient selection enough to yield a 15% survival benefit over traditional designs — based solely on early study data.
Clinical Trial Innovation
Institution: InstaDeep (February 2026)
InstaDeep released NTv3, a genomics foundation model treating the genome as a long-range 3D system. Includes pre-trained checkpoints and PyTorch notebooks for long-context inference, functional-track prediction, genome annotation, variant analysis, and guided sequence generation for enhancer design.
Genomics Foundation Model
💻 Top GitHub Repos of the Week
⭐ 2,100+ stars | Python | Active development
The essential PyTorch toolkit for medical image preprocessing in deep learning pipelines. Supports MRI, CT, PET, and other modalities with operations like random motion artifacts, bias field simulation, and spatial transformations. The preprocessing layer every diagnostic AI needs.
⭐ 2,000+ stars | Python | Core scverse ecosystem
The standard Python library for single-cell RNA-seq analysis. From preprocessing and visualization to clustering and differential expression, Scanpy scales to over 100 million cells — essential for atlas-scale projects like the Human Cell Atlas.
⭐ 2,300+ stars | Python | Standard in bioimage analysis
The go-to multi-dimensional image viewer for biological data. Handles 2D, 3D, and time-series microscopy data with an extensible plugin system, widely used in neuroscience, cell biology, and pathology for interactive visualization and annotation.
⭐ Trending (419 upvotes) | TypeScript | Security scanning
Answers "Is this safe to install?" for code packages, IDE extensions, and AI models across VS Code, JetBrains, npm, and Hugging Face. Critical for bioinformatics teams that regularly install pip/conda packages and HF models to protect research pipelines.
⭐ Trending (546 upvotes) | Multi-language | AI agent orchestration
A turbocharged IDE that runs multiple AI coding agents simultaneously in isolated sandboxes. Monitor all agents from one dashboard — perfect for bioinformatics developers parallelizing analysis scripts and running pipeline experiments concurrently.
📖 Learning Blog of the Week
Author: InstaDeep Research Team | Publication: InstaDeep Blog
InstaDeep's February 2026 release of the Nucleotide Transformer v3 came with exceptional educational resources. The blog walks through the architecture and applications of their genomics foundation model, accompanied by hands-on PyTorch notebooks covering variant analysis to enhancer design. The most accessible on-ramp to genomics AI available today.
What you'll learn:
- How to use genomics foundation models for long-context inference and variant analysis
- Practical PyTorch notebooks for genome annotation and functional-track prediction
- Guided sequence generation techniques for synthetic biology enhancer design
🛠️ Top AI Products of the Week
823 upvotes | Category: Hosted AI Agents
A fully managed, hosted version of OpenClaw — the most popular open-source AI agent. Eliminates infrastructure burden for research labs: deploy automated research assistants, data processing agents, and lab workflow automation without managing servers or security.
620 upvotes | Category: AI Productivity
Transfer your preferences, projects, and context from other AI providers into Claude with one copy-paste. Research teams who built months of context in ChatGPT can migrate without losing accumulated domain expertise and project specifications.
546 upvotes | Category: Developer Tools
Run multiple Claude Code, Codex, and other coding agents simultaneously in isolated sandboxes. Monitor all agents from one place with built-in diff viewer and editor. Ship code at unprecedented speed.
361 upvotes | Category: Communication AI
Converts accented English into neutral American English on the listener's side in real time, fully on-device. Built for global research teams where accent differences slow critical communications across Zoom, Teams, and Meet.
⚠️ AI Criticism & Concerns
Critical Perspectives on AI Ethics and Safety
This week's AI ethics landscape was dominated by the unprecedented Anthropic-Pentagon standoff and the escalating Grok deepfake crisis — both forcing urgent conversations about AI governance.
Trump Administration Blacklists Anthropic After Pentagon Safety Standoff
The Trump administration ordered all federal agencies to cease using Anthropic technology after the company refused to remove restrictions preventing Claude from being used for mass domestic surveillance or fully autonomous weapons. Defense Secretary Hegseth designated Anthropic a "supply chain risk." The incident raises a fundamental question: should AI companies have the right to restrict military applications?
Read more at CNBC
OpenAI Rushes to Fill Pentagon Void with Classified Military AI Deal
Hours after Anthropic's ban, OpenAI announced a deal for classified Pentagon networks. A company that once championed AI safety now races to monetize military contracts its competitor refused on ethical grounds. The deal reignites debates about whether safety commitments survive when billions in government contracts are at stake.
Read more at NPR
Grok Deepfake Scandal: 6,700 Images Per Hour, Global Crackdown
Elon Musk's Grok generated 6,700 sexually suggestive or nudified images per hour — 84 times more than the top 5 deepfake websites combined. An analysis showed 2% appeared to depict minors. The EU ordered data retention, Paris prosecutors raided X's offices, multiple countries blocked Grok, and a class action lawsuit has been filed.
Read more at TechPolicy.Press
AI Regulation Becomes Bipartisan Priority in U.S. Congress
Driven by the Anthropic-Pentagon standoff and Grok scandal, AI regulation has emerged as a rare bipartisan issue. Both parties converge on binding regulation, with the EU AI Act's high-risk provisions taking effect August 2026 — creating global regulatory momentum reshaping how AI operates in healthcare and defense.
Read more
Closing Note
This week crystallized the tensions defining AI in 2026. On one side, Lilly's LillyPod shows pharma becoming its own AI powerhouse — building infrastructure rivaling Silicon Valley. On the other, the Anthropic-Pentagon standoff and Grok scandal show the guardrails question is no longer theoretical. When governments ban companies for having safety principles, and others rush to fill the void, we must ask hard questions about who controls these tools and for what purpose. The biology and healthcare community has a unique role: we know what's at stake when AI goes wrong in high-stakes settings. Stay engaged, stay critical.
Thank you for reading PythRaSh's AI Newsletter! If you found this week's insights valuable, please share them with colleagues and friends interested in the intersection of AI and biology.
Have feedback or suggestions? Reply to this email - I read every response!
See you next week!
Md Rasheduzzaman
|